We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$3.17B
AUM Growth
+$561M
Cap. Flow
+$1.16B
Cap. Flow %
36.62%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$16.4M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$9.99M
3
TSLA icon
Tesla
TSLA
+$7.93M
4
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
5
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.52%
2 Healthcare 9.63%
3 Energy 0.42%
4 Industrials 0.14%
5 Consumer Staples 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CASC
301
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-28
Closed -$32K
CEMP
302
DELISTED
Cempra, Inc.
CEMP
– –
-70,804
Closed -$1.06M
BSTG
303
DELISTED
Biostage, Inc. Common Stock
BSTG
– –
-55,621
Closed -$451K
WINT
304
CALL
DELISTED
Windtree Therapeutics Inc
WINT
– –
-102
Closed -$262K
WINT
305
DELISTED
Windtree Therapeutics Inc
WINT
– –
-4,643
Closed -$120K
GEVA
306
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-145,200
Closed -$9.99M
GEVA
307
PUT
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-1,452
Closed -$9.99M
SLXP
308
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-2,000
Closed -$242K
NPSP
309
PUT
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-514
Closed -$1.34M
AVNR
310
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-2,382
Closed -$2.84M
BAXS
311
DELISTED
BAXANO SURGICAL INC COM STK (DE)
BAXS
– –
-1,269,646
Closed -$232K
IMUC
312
PUT
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
– –
-6
Closed -$21K
MDVN
313
PUT
DELISTED
MEDIVATION, INC.
MDVN
– –
-52
Closed -$257K
OXGN
314
CALL
DELISTED
OXIGENE INC COM
OXGN
– –
-344
Closed -$74K
OXGN
315
PUT
DELISTED
OXIGENE INC COM
OXGN
– –
-222
Closed -$48K
9 10 11 12
13

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17B, up 22% from $2.6B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $1.16B of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1M.

By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 92% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1M.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Acadia Healthcare in Q4 2014, selling an estimated $16.4M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17B portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17B.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.